Iron status in Dutch and Finnish blood donor and general populations: A cross-cohort comparison study.
blood donation
cross‐cohort comparison
ferritin
iron deficiency
iron supplementation
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
15 Apr 2024
15 Apr 2024
Historique:
revised:
18
03
2024
received:
14
02
2024
accepted:
28
03
2024
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
16
4
2024
Statut:
aheadofprint
Résumé
Blood donors are at risk of developing iron deficiency (ID) (ferritin <15 μg/L, World Health Organization definition). Blood services implement different strategies to mitigate this risk. Although in Finland risk group-based iron supplementation is in place, no iron supplementation is provided in the Netherlands. We aim to describe differences in ferritin levels and ID prevalence in donor and general populations in these countries. Six cohorts, stratified based on sex, and for women age, in the Netherlands and Finland were used to evaluate differences in ferritin levels and ID between donor populations (Donor InSight-III and FinDonor 10,000) and general populations (Prevention of Renal and Vascular End-Stage Disease [PREVEND], FinRisk 1997 and Health 2000) and newly registered Dutch donors. Multivariable logistic regression was used to quantify associations of various explanatory factors with ID. In total, 13,443 Dutch and 13,933 Finnish subjects were included. Donors, except for women aged ≤50 years old in Finland, had lower median ferritin levels compared with the general population and new donors. Dutch regular blood donors had higher or similar prevalence of ID as compared with the Dutch general population, including new donors. In contrast, Finnish donors showed similar prevalence of ID compared with the general population, except for a markedly lower prevalence in ≤50-year-old women who routinely receive iron supplements when donating. Iron status in blood donors differs from that in the general population. The Finnish blood service donor management policy, for example, iron supplementation for risk groups, seemingly protects young female blood donors from developing ID.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Blood donors are at risk of developing iron deficiency (ID) (ferritin <15 μg/L, World Health Organization definition). Blood services implement different strategies to mitigate this risk. Although in Finland risk group-based iron supplementation is in place, no iron supplementation is provided in the Netherlands. We aim to describe differences in ferritin levels and ID prevalence in donor and general populations in these countries.
MATERIALS AND METHODS
METHODS
Six cohorts, stratified based on sex, and for women age, in the Netherlands and Finland were used to evaluate differences in ferritin levels and ID between donor populations (Donor InSight-III and FinDonor 10,000) and general populations (Prevention of Renal and Vascular End-Stage Disease [PREVEND], FinRisk 1997 and Health 2000) and newly registered Dutch donors. Multivariable logistic regression was used to quantify associations of various explanatory factors with ID.
RESULTS
RESULTS
In total, 13,443 Dutch and 13,933 Finnish subjects were included. Donors, except for women aged ≤50 years old in Finland, had lower median ferritin levels compared with the general population and new donors. Dutch regular blood donors had higher or similar prevalence of ID as compared with the Dutch general population, including new donors. In contrast, Finnish donors showed similar prevalence of ID compared with the general population, except for a markedly lower prevalence in ≤50-year-old women who routinely receive iron supplements when donating.
CONCLUSION
CONCLUSIONS
Iron status in blood donors differs from that in the general population. The Finnish blood service donor management policy, for example, iron supplementation for risk groups, seemingly protects young female blood donors from developing ID.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Sanquin's Research Programming Committee
ID : PPOC19-02
Organisme : Finnish Red Cross Blood Service
Informations de copyright
© 2024 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion.
Références
Prinsze FJ, de Groot R, Timmer TC, Zalpuri S, van den Hurk K. Donation‐induced iron depletion is significantly associated with low hemoglobin at subsequent donations. Transfusion. 2021;61:3344–3352.
Vinkenoog M, van den Hurk K, van Kraaij M, van Leeuwen M, Janssen MP. First results of a ferritin‐based blood donor deferral policy in The Netherlands. Transfusion. 2020;60:1785–1792.
Schotten N, Pasker‐de Jong PC, Moretti D, Zimmermann MB, Geurts‐Moespot AJ, Swinkels DW, et al. The donation interval of 56 days requires extension to 180 days for whole blood donors to recover from changes in iron metabolism. Blood. 2016;128:2185–2188.
Baart AM, van den Hurk K, de Kort WL. Minimum donation intervals should be reconsidered to decrease low hemoglobin deferral in whole blood donors: an observational study. Transfusion. 2015;55:2641–2644.
Wet inzake bloedvoorziening. 1997.
Cable RG. Hemoglobin determination in blood donors. Transfus Med Rev. 1995;9:131–144.
Sweegers MA‐O, Zalpuri S, Quee FA, Huis in ′t Veld EMJ, Prinsze FJ, Hoogendijk EO, et al. Ferritin measurement IN donors‐effectiveness of iron monitoring to diminish iron deficiency and low haemoglobin in whole blood donors (FIND'EM): study protocol for a stepped wedge cluster randomised trial. Trials. 2020;21:21.
de Kort W, Prinsze F, Nuboer G, Twisk J, Merz EM. Deferral rate variability in blood donor eligibility assessment. Transfusion. 2019;59:242–249.
Goldman M, Magnussen K, Gorlin J, Lozano M, Speedy J, Keller A, et al. International forum regarding practices related to donor haemoglobin and iron. Vox Sang. 2016;111:449–455.
Vuk T, Magnussen K, De Kort W, Folléa G, Liumbruno GM, Schennach H, et al. International forum: an investigation of iron status in blood donors. Blood Transfus. 2017;15:20–41.
Timmer TC, de Groot R, Habets K, Merz EM, Prinsze FJ, Atsma F, et al. Donor InSight: characteristics and representativeness of a Dutch cohort study on blood and plasma donors. Vox Sang. 2018;114:117–128.
Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–1782.
Lobier M, Niittymäki P, Nikiforow N, Palokangas E, Larjo A, Mattila P, et al. FinDonor 10 000 study: a cohort to identify iron depletion and factors affecting it in Finnish blood donors. Vox Sang. 2020;115:36–46.
Borodulin K, Tolonen H, Jousilahti P, Jula A, Juolevi A, Koskinen S, et al. Cohort profile: the national FINRISK study. Int J Epidemiol. 2018;47:696–696i.
Heistaro S. Methodology report: health 2000 survey. Helsinki: National Public Health Institute. 2008.
Bürkner P‐C. brms: an R package for Bayesian multilevel models using Stan. J Stat Softw. 2017;80:1–28.
Gabry J, Simpson D, Vehtari A, Betancourt M, Gelman A. Visualization in Bayesian workflow. J R Stat Soc Ser A Stat Soc. 2019;182:389–402.
Patel EU, White JL, Bloch EM, Grabowski MK, Gehrie EA, Lokhandwala PM, et al. Association of blood donation with iron deficiency among adolescent and adult females in the United States: a nationally representative study. Transfusion. 2019;59:1723–1733.
Vinkenoog M, Toivonen J, Brits T, de Clippel D, Compernolle V, Karki S, et al. An international comparison of haemoglobin deferral prediction models for blood banking. Vox Sang. 2023;118:430–439.
Maghsudlu M, Nasizadeh S, Toogeh GR, Zandieh T, Parandoush S, Rezayani M. Short‐term ferrous sulfate supplementation in female blood donors. Transfusion. 2008;48:1192–1197.
Lobier M, Castrén J, Niittymäki P, Palokangas E, Partanen J, Arvas M. The effect of donation activity dwarfs the effect of lifestyle, diet and targeted iron supplementation on blood donor iron stores. PloS One. 2019;14:e0220862.
Mast AE, Szabo A, Stone M, Cable RG, Spencer BR, Kiss JE. The benefits of iron supplementation following blood donation vary with baseline iron status. Am J Hematol. 2020;95:784–791.
Bialkowski W, Kiss JE, Wright DJ, Cable R, Birch R, D'Andrea P, et al. Estimates of total body iron indicate 19 mg and 38 mg oral iron are equivalent for the mitigation of iron deficiency in individuals experiencing repeated phlebotomy. Am J Hematol. 2017;92:851–857.
OECD. Fertility rates (indicator). 2024. https://doi.org/10.1787/8272fb01-en Last accessed 2024 Jan 15.
Lethaby A, Wise MR, Weterings MA, Bofill Rodriguez M, Brown J. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;2:CD000154.
Kang W, Barad A, Clark AG, Wang Y, Lin X, Gu Z, et al. Ethnic differences in iron status. Adv Nutr. 2021;12:1838–1853.
Zalpuri S, Romeijn B, Allara E, Goldman M, Kamel H, Gorlin J, et al. Variations in hemoglobin measurement and eligibility criteria across blood donation services are associated with differing low‐hemoglobin deferral rates: a BEST collaborative study. Transfusion. 2020;60:544–552.
Shehu E, Hofmann A, Clement M, Langmaack A‐C. Healthy donor effect and satisfaction with health. Eur J Health Econ. 2015;16:733–745.
Braga F, Pasqualetti S, Frusciante E, Borrillo F, Chibireva M, Panteghini M. Harmonization status of serum ferritin measurements and implications for use as marker of iron‐related disorders. Clin Chem. 2022;68:1202–1210.